Korsuva (Difelikefalin Acetate) Patent Expiration, LOE Window & CMS Spending

Korsuva (Difelikefalin Acetate) by Vifor (International): FDA Orange Book core substance LOE 2032-11-12, 0 AB generics, $2.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorVifor (International)
FDA Application & PathwayN214916 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2032-11-12
Last Listed Patent or Exclusivity Date2032-11-12
Orange Book Patents (*PED Extensions)12 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.7M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$2.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel